Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) initiates the infection
process by binding to the viral cellular receptor angiotensin-converting enzyme 2 through …

Since the onset of the coronavirus disease 2019 (COVID-19), numerous neutralizing
antibodies (NAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …

Neutralizing antibodies (NAbs) are central players in the humoral immunity that defends the
body from SARS-CoV-2 infection by blocking viral entry into host cells and neutralizing their …

A newly identified novel coronavirus (SARS-CoV-2) is causing pneumonia-associated
respiratory syndrome across the world. Epidemiology, genomics, and pathogenesis of the …

Coronavirus (CoV) disease 2019 (COVID-19) caused by severe acute respiratory syndrome
(SARS)-CoV-2 (also known as 2019-nCoV) is threatening global public health, social …

Neutralizing monoclonal antibodies (nAbs) to severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) represent promising candidates for clinical intervention against …

The rapid emergence of Coronavirus disease-2019 (COVID-19) caused by severe acute
respiratory syndrome 2 coronavirus (SARS-CoV-2) as a pandemic that presents an urgent …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a recently emerged
pathogenic human coronavirus that belongs to the sarbecovirus lineage of the genus …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spreads worldwide and
leads to an unprecedented medical burden and lives lost. Neutralizing antibodies provide …

Most human monoclonal antibodies (mAbs) neutralizing SARS-CoV-2 recognize the spike
(S) protein receptor-binding domain and block virus interactions with the cellular receptor …